Risk Assessment with Low Pass Whole Genome Sequencing of Cell Free DNA before CD19 CAR T Cells for Large B Cell Lymphoma

The authors evaluated low pass whole genome sequencing of cell free DNA prior to CD19 CAR T cell therapy as a new approach for risk stratification.